Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca has built resilient supply chains in U.S., China: CEO
12:08pm, Tuesday, 29'th Apr 2025
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.
Pharma firms maastraz
12:06pm, Tuesday, 29'th Apr 2025
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript
11:46am, Tuesday, 29'th Apr 2025
AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - Exec
AstraZeneca CEO talks tariffs, first quarter earnings
11:35am, Tuesday, 29'th Apr 2025
AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted
AstraZeneca shares claw their way back into green after revenue miss
11:17am, Tuesday, 29'th Apr 2025
After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the res
Here's Why Astrazeneca (AZN) is a Strong Value Stock
10:40am, Tuesday, 29'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
10:36am, Tuesday, 29'th Apr 2025
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
10:15am, Tuesday, 29'th Apr 2025
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
AstraZeneca shows its strength despite sales miss
10:02am, Tuesday, 29'th Apr 2025
AstraZeneca PLC (LSE:AZN) has once again shown why it sits at the top table of global pharmaceuticals. Although first-quarter sales missed City forecasts by a whisker, profits came in well ahead of e
AstraZeneca to keep 2025 forecast if US pharmaceutical tariffs in line with other sectors
05:16am, Tuesday, 29'th Apr 2025
The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the European Union, provided they
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
04:10am, Tuesday, 29'th Apr 2025
The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.
AstraZeneca shares fall 4% after Q1 revenue miss
03:16am, Tuesday, 29'th Apr 2025
Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance fro
AstraZeneca says may face further import tax fine from China
02:10am, Tuesday, 29'th Apr 2025
AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of $1.6 million, adding that a fine of one to five times that amount may be le
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
12:00pm, Monday, 28'th Apr 2025
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced
Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science
06:00pm, Thursday, 24'th Apr 2025
VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned su
